Scholarlink

Objectives <p>To evaluate the course and predictors of outcome of metabolic dysfunction-associated steatotic liver disease (MASLD).</p> Methods <p>Records of 100 obese children with MASLD were reviewed for change in body mass index (BMI) and alanine aminotransferase (ALT) levels.</p> Results <p>A total of 100 (73 boys) children with mean (SD) age 12.1 (2.8) years followed for 2.0 (1.6) years were included. Normalization in ALT levels occurred in 72 (72%) at 1.1 (0.8) years of follow-up; 17 (23.6%) relapsed after 1.6 (1.3) years. Sustained remission (<i>n</i> = 55; 55%) was associated with greater BMI Z-score reduction (%) [median (q1, q3) 15.3 (5.1, 25.5) vs. 3.4 (− 4.3, 11.1); <i>P</i> &lt; 0.001]. Multivariate regression identified BMI Z-score reduction as the only predictor of remission (OR 6.67, 95%CI 1.54–33.3; <i>P</i> = 0.007). ROC analysis showed BMI Z-score reduction of 13.8% predicted remission with an area under curve of 0.72 (95%CI: 0.62, 0.82; <i>P</i> &lt; 0.001).</p> Conclusion <p>Pediatric MASLD has a variable course, with remission dependent on the reduction in BMI Z-score.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical Course and Predictors of Metabolic Dysfunction Associated Steatotic Liver Disease in Obese Children and Adolescents

  • 期刊论文

  • 发表日期：

    2026年2月17日

查看全文
  • R. Narayanan,
  • Vibha Yadav,
  • Jaya Agarwal,
  • Rishi Shukla,
  • Anurag Bajpai

摘要

Objectives

To evaluate the course and predictors of outcome of metabolic dysfunction-associated steatotic liver disease (MASLD).

Methods

Records of 100 obese children with MASLD were reviewed for change in body mass index (BMI) and alanine aminotransferase (ALT) levels.

Results

A total of 100 (73 boys) children with mean (SD) age 12.1 (2.8) years followed for 2.0 (1.6) years were included. Normalization in ALT levels occurred in 72 (72%) at 1.1 (0.8) years of follow-up; 17 (23.6%) relapsed after 1.6 (1.3) years. Sustained remission (n = 55; 55%) was associated with greater BMI Z-score reduction (%) [median (q1, q3) 15.3 (5.1, 25.5) vs. 3.4 (− 4.3, 11.1); P < 0.001]. Multivariate regression identified BMI Z-score reduction as the only predictor of remission (OR 6.67, 95%CI 1.54–33.3; P = 0.007). ROC analysis showed BMI Z-score reduction of 13.8% predicted remission with an area under curve of 0.72 (95%CI: 0.62, 0.82; P < 0.001).

Conclusion

Pediatric MASLD has a variable course, with remission dependent on the reduction in BMI Z-score.